Quantcast

Latest Recombinant proteins Stories

2014-07-08 23:09:30

Market Size - $1,136.2 million in 2013, Market Growth - CAGR of 15.0%, Market Trends– Introduction of ultra-long and ultra-fast acting insulin such as Tresiba new report by Grand View Research. View full report with TOC - http://www.grandviewresearch.com/industry-analysis/cis-insulin-market. San Francisco, California (PRWEB) July 08, 2014 The CIS market for insulin and insulin products is expected to reach USD 3,008.5 million by 2020 growing at a CAGR of 15.0%, according to a new study...

2014-07-08 08:31:22

- Toujeo dossier already accepted by EMA - PARIS, July 8, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), an investigational basal insulin. The acceptance of the NDA follows the acceptance of the marketing authorization dossier for Toujeo by the European Medicines Agency (EMA) for...

2014-06-30 23:11:03

ReportsnReports.com offers Human Insulin Market by Product Type (Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed), by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2018 research report in its store. This report is spread across 250 pages and provides 112 data tables as well as 43 figures to support the business intelligence and global human insulin market information provided in the...

2014-06-27 12:26:19

DALLAS, June 27, 2014 /PRNewswire/ -- According to the new market research report, "Human Insulin Market by Product Type (Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed), by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2018" published by MarketsandMarkets, The global Human Insulin Market crossed $23 Billion in 2013 and is poised to grow at a high double-digit CAGR from...

2014-06-27 08:25:26

First biosimilar insulin to receive CHMP positive opinion in the EU INDIANAPOLIS and INGELHEIM, Germany, June 27, 2014 /PRNewswire/ -- The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes. The new insulin glargine product from Eli Lilly and Company and Boehringer Ingelheim is the first biosimilar insulin...

2014-06-27 08:25:19

First biosimilar insulin to receive CHMP positive opinion in the EU INDIANAPOLIS and RIDGEFIELD, Conn., June 27, 2014 /PRNewswire/ -- The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes. The new insulin glargine product from Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim is the first...

2014-06-20 23:06:47

ResearchMoz.us includes new market research report "Insulin Delivery Devices Market to 2019 - Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers" to its huge collection of research reports. Albany, NY (PRWEB) June 20, 2014 The report provides comprehensive information on the key trends affecting these segments, and key analytical content on the market dynamics. The report also reviews the competitive landscape, analyzes each segment’s...

2014-06-20 23:06:12

Market Size - $1,326.6 Mn 2013, Market Growth - CAGR of 16.2%, Market Trends –Innovations such as ultra-long acting analogs new report by Grand View Research. View full report with TOC - http://www.grandviewresearch.com/industry-analysis/latin-merica-insulin-market. San Francisco, California (PRWEB) June 20, 2014 The Latin America market for Insulin is expected to reach USD 3,760.7 million by 2020, according to a new study by Grand View Research, Inc. Growing prevalence of diabetes...

2014-06-19 08:30:01

Latest delivery device advancement in the basal insulin category PLAINSBORO, N.J., June 19, 2014 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced the availability of its newest prefilled insulin delivery device Levemir(®) FlexTouch(®) (insulin detemir [rDNA origin] injection) in the United States. This device represents an advancement in insulin delivery and is based on years of feedback from endocrinologists, certified diabetes educators, primary care...

2014-06-18 23:12:11

Global Type 1 Diabetes Market 2014-2018 a research report available at ReportsnReports.com. Dallas, Texas (PRWEB) June 18, 2014 The key vendors in the Global Type 1 Diabetes market are increasing their penetration in the emerging markets. Recent years have witnessed an increase in investment in manufacturing sites based in these countries with the intention to enhance the production of drugs such as insulin for local or global markets. For instance, the Frankfurt site is a key...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related